Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, ...

Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...